Crinetics Pharmaceuticals, Inc.
CRNX
$37.48
$0.571.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 74.22% | 4,208.39% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 74.22% | 4,208.39% | |||
| Cost of Revenue | 16.43% | -4.79% | |||
| Gross Profit | -11.98% | 11.46% | |||
| SG&A Expenses | -5.34% | 2.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.07% | -2.03% | |||
| Operating Income | -5.02% | 6.26% | |||
| Income Before Tax | -4.25% | 5.73% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.10% | 5.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.10% | 5.59% | |||
| EBIT | -5.02% | 6.26% | |||
| EBITDA | -4.93% | 6.29% | |||
| EPS Basic | 4.91% | 6.47% | |||
| Normalized Basic EPS | 4.76% | 6.60% | |||
| EPS Diluted | 4.91% | 6.47% | |||
| Normalized Diluted EPS | 4.76% | 6.60% | |||
| Average Basic Shares Outstanding | 9.47% | 0.94% | |||
| Average Diluted Shares Outstanding | 9.47% | 0.94% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||